Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mavodelpar - OnKure Therapeutics

Next Previous
X
Search
Drug Profile

Mavodelpar - OnKure Therapeutics

Alternative Names: HPP 593; REN-001 - OnKure Therapeutics

Latest Information Update: 14 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer High Point Pharmaceuticals; OnKure Therapeutics; vTv Therapeutics LLC
  • Class Acetic acids; Alkenes; Alkynes; Antihyperglycaemics; Antihyperlipidaemics; Fluorobenzenes; Morpholines; Phenyl ethers; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial myopathies; Inborn error metabolic disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Inborn error metabolic disorders; Mitochondrial myopathies
  • Discontinued Diabetes mellitus; Dyslipidaemias; Glycogen storage disease type V; Muscle fatigue

Most Recent Events

  • 04 Oct 2024 Reneo Pharmaceuticals has merged with OnKure Therapeutics to form OnKure Therapeutics
  • 09 Feb 2024 Reneo Pharmaceuticals terminates the phase II/III STRIDE AHEAD trial for Mitochondrial myopathies in Australia, Germany, Denmark, Hungary, Belgium, Netherlands, Spain, Canada, France, Italy, New Zealand and United Kingdom (PO), because the parent study failed to show therapeutic effect (NCT05267574) (EudraCT2021-003471-34)
  • 31 Dec 2023 Mavodelpar - Reneo Pharmaceuticals is available for licensing as of 31 Dec 2023. https://reneopharma.com/

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top